Delivering Innovative Diagnostics for Personalized Curative Therapies
Dengue Fever - A global fast-emerging pandemic-prone viral disease
20,000
400,000,000
people have Dengue infections every year
500,000
people progressed on to develop Severe Dengue and required hospitalization
hospitalized Severe Dengue patients die from the disease
US$14,600,000,000
worth of socioeconomic cost
Source: Malaria Consortium
The Challenge
Currently, doctors are unable to predict the progress of the disease due to the lack of a Severe Dengue prediction test. Patients often end up being admitted to hospital even when they do not progress to Severe Dengue. This leads to overhospitalization in both developing and developed countries.
The Solution
StratifiCare™ has discovered a panel of biomarkers which are able to determine the progress of Dengue Fever. Patients who are predicted not to progress to Severe Dengue can be managed at outpatient settings instead. This reduces the overhospitalization issue faced by hospitals and relieves healthcare burden in countries.
SUPPORTING THE SDGS
The United Nations has defined a set of 17 Sustainable Development Goals (SDGs) that address global social and economic development issues. As a responsible medical technology provider, StratifiCare adopts the SDG framework.
By developing quality, innovative diagnostic solutions, we pledge to facilitate access to quality essential health services, for the general and the most disadvantaged population.